Please assess the completion status of the following clinical trial:

Trial Title: Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Understands the study procedures, alternative treatment available, and risks involved with the study, and voluntarily agrees to participate by giving written informed consent~2. Male or non-pregnant, non-lactating female diagnosed with T1D for at least 24 months prior to Screening.~3. Aged 18 to 64 years of age, inclusive~4. On a stable insulin regimen for 21 days prior to Screening (no greater than ± 20% variability in total daily dose)~5. Have a plasma C-peptide level \< 0.6 ng/mL at Screening~6. Have an HbA1c \< 10% at Screening~7. Body mass index (BMI) in the range of ≥ 18 to ≤ 35 kg/m2 at Screening~8. For women of childbearing potential, there is a requirement for a negative urine pregnancy test at Screening and for agreement to use contraception throughout the study and for 7 days after the last dose of study drug. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera® (medroxyprogesterone acetate), Norplant® System (levonorgestrel), an intra-uterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.~9. Fasting Serum triglyceride concentration \< 200 mg/dL~Exclusion Criteria:~1. Currently being treated with pramlintide or has discontinued pramlintide within 21 days of Screening~2. Currently using an insulin pump~3. Has renal insufficiency (serum creatinine \<3.0 mg/dL) or end-stage renal disease requiring renal replacement therapy~4. Has hepatic disease, including serum ALT or AST ≥3 times the upper limit of normal (ULN)~5. Has hepatic synthetic insufficiency (serum albumin \<3.0 g/dL)~6. Has a hematocrit value that is exclusionary: Female \<35.5% and Male \<38.3%~7. Has a hemoglobin value that is exclusionary: Female \<11.5 g/dL and Male \<12.5 g/dL~8. Has out-of-range systolic or diastolic BP readings at Screening (systolic BP \<90 or \>150 mm Hg or diastolic BP \<50 or \>100 mm Hg)~9. Has clinically significant ECG abnormalities at Screening~10. Has congestive heart failure, NYHA Class III or IV~11. Has history of myocardial infarction, unstable angina, or revascularization within 6 months prior to Screening~12. Has history of a cerebrovascular accident in 6 months prior to Screening with major neurological deficits~13. Has active malignancy within 5 years prior to Screening (exception: basal cell or squamous cell skin cancers)~14. Has had major surgical operation within 60 days prior to Screening or planned surgical operation during the study~15. Has a seizure disorder (other than with suspected or documented hypoglycemia)~16. Has a current bleeding disorder, treatment with anticoagulants, or platelet count \<50 ×10\^9/L~17. Has a history of allergies or significant hypersensitivity to pramlintide or any pramlintide-related products or to any of the excipients in the investigational formulation~18. Has a history of positive test result for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)~19. Has a concurrent illness not controlled by a stable therapeutic regimen~20. Tests positive for drugs of abuse at Screening. Subjects testing positive for tetrahydrocannabinol (THC) at Screening or reporting active marijuana use will be allowed to participate in the study at the discretion of the investigator.~21. Has active substance or alcohol abuse (\>21 drinks/week for males or \>14 drinks/week for females)~22. Has participated in other studies involving administration of an investigational drug within 30 days or 5 half-lives prior to Screening (whichever is longer) or during participation in the current study~23. There is any reason the investigator deems exclusionary~24. Has donated blood within 8 weeks prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- PRAM9 to Regular Insulin to Regular Insulin+pramlintide (Type: EXPERIMENTAL): Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin (Humulin®) to Regular Insulin+pramlintide (Symlin® pen) as separate SC injections
- Regular Insulin to Regular Insulin+pramlintide to PRAM9 (Type: EXPERIMENTAL): Regular Insulin (Humulin®) to Regular Insulin+pamlintide (Symlin® pen) as separate SC injections to PRAM9
- Regular Insulin+pramlintide to PRAM9 to Regular Insulin (Type: EXPERIMENTAL): Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin
- PRAM9 to Regular Insulin+pramlintide to Regular Insulin (Type: EXPERIMENTAL): Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Regular Insulin
- Regular Insulin to PRAM9 to Regular Insulin+pramlintide (Type: EXPERIMENTAL): Regular Insulin (Humulin®) to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin+pramlintide (Symlin® pen) as separate SC injections to Regular Insulin
- Regular Insulin+pramlintide to Regular Insulin to PRAM9 (Type: EXPERIMENTAL): Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin to Xeris pramlintide + insulin co-formulation (PRAM9)

Based on this trial design, predict the completion outcome and termination type (if applicable).